CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionReturn on equity is -149.7%, lower than 95% of its Medical Devices peers (median 3%)
- FinancialsAltman Z-Score 1.05: distress zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
454.34MUSDvs all stocks (USD)
Revenue (TTM)
40.61MUSDvs all stocks (USD)
Profit Margin
-71.57%vs Medical Devices peers
Beta
1.24xvs all stocks
52-Week Change
37.98%vs all stocks
Market Capitalization
454.34MUSDvs all stocks (USD)
Enterprise Value
497.93MUSDvs all stocks (USD)
Forward P/E
-16.02xvs Medical Devices peers
Price to Sales (TTM)
11.12xvs Medical Devices peers
Price to Book (MRQ)
23.98xvs Medical Devices peers
Enterprise to Revenue
12.26xvs Medical Devices peers
Enterprise to EBITDA
-21.09xvs Medical Devices peers
Gross Margin
63.95%vs Medical Devices peers
Profit Margin
-71.57%vs Medical Devices peers
Operating Margin
-69.90%vs Medical Devices peers
Return on Assets (TTM)
-24.98%vs Medical Devices peers
Return on Equity (TTM)
-149.72%vs Medical Devices peers
Revenue (TTM)
40.61MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.41USDUpdated Jul 18, 2026Quarterly Revenue Growth
42.90%vs Medical Devices peers
Gross Profit (TTM)
25.32MUSDvs all stocks (USD)
EBITDA (TTM)
-23.61MUSDvs all stocks (USD)
Net Income (TTM)
-29.07MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
42.93%vs Medical Devices peers
Operating Cash Flow (TTM)
-25.72MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-11.63MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
36.97MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
14.28MUSDFY2025 · Dec 31, 2025Gross Profit
22.69MUSDFY2025 · Dec 31, 2025Operating Income
-24.16MUSDvs all stocks (USD)
Pre-tax Income
-25.48MUSDFY2025 · Dec 31, 2025Income Tax Expense
55.00KUSDFY2025 · Dec 31, 2025Net Income
-25.54MUSDFY2025 · Dec 31, 2025EBIT
-23.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-20.86MUSDFY2025 · Dec 31, 2025Research & Development
13.90MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
32.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.39MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-25.54MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-16.03MUSDFY2025 · Dec 31, 2025Free Cash Flow
-16.55MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.24M of depreciation against 522K of capital expenditure, and its own free-cash-flow line reads -24.45M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
46.97MUSDFY2025 · Dec 31, 2025Income Tax Paid
69.00KUSDFY2025 · Dec 31, 2025Interest Paid
908.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-25.54MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.24MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
991.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-268.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.63MUSDFY2025 · Dec 31, 2025Capital Expenditures
-522.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
1.14MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
615.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
48.09MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.86MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
49.49MUSDFY2025 · Dec 31, 2025Shares Outstanding
29.99MSharesUpdated Jul 18, 2026Float Shares
26.27MSharesUpdated Jul 18, 2026Shares Short
4.30MSharesUpdated Jul 18, 2026Short Ratio
4.13daysvs all stocks
Short % of Shares Outstanding
14.84%vs all stocks
% Held by Insiders
5.48%vs all stocks
% Held by Institutions
50.62%vs all stocks
Total Cash (MRQ)
35.59MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.19USDUpdated Jul 18, 2026Total Debt (MRQ)
63.59MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
3.37xvs Medical Devices peers
Current Ratio (MRQ)
5.79xvs Medical Devices peers
Book Value per Share (MRQ)
0.6280USDUpdated Jul 18, 2026Total Assets
97.75MUSDvs all stocks (USD)
Total Current Assets
63.60MUSDFY2025 · Dec 31, 2025Total Liabilities
69.73MUSDFY2025 · Dec 31, 2025Total Non-current Assets
34.15MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
58.96MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.92MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.55MUSDFY2025 · Dec 31, 2025Inventory
8.36MUSDFY2025 · Dec 31, 2025Accounts Payable
1.26MUSDFY2025 · Dec 31, 2025Short-term Debt
694.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
1.67MUSDFY2025 · Dec 31, 2025Long-term Debt
57.54MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
489.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
294.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-216.91MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
28.02MUSDvs all stocks (USD)
52-Week Low
8.27USDUpdated Jul 18, 202652-Week High
30.10USDUpdated Jul 18, 202652-Week Change
37.98%vs all stocks
Beta
1.24xvs all stocks
50-Day MA
14.41USDUpdated Jul 18, 2026200-Day MA
14.85USDUpdated Jul 18, 2026Avg 10-Day Volume
428.53KSharesUpdated Jul 18, 2026Avg 30-Day Volume
853.04KSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-1.00USDUpdated Jul 18, 2026Other Income / Expense
-146.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -149.7%, lower than 95% of its Medical Devices peers (median 3%)Significant
Return on equity: -1.50Industry median: 0.03Industry P5: -0.69Peers compared: 102
Debt-to-equity is 3.37×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 3.37Industry median: 0.11Industry P95: 1.20Peers compared: 102
Price-to-book is 23.98×, higher than 95% of its Medical Devices peers (median 2.69×)Significant
Price-to-book: 23.98Industry median: 2.69Industry P95: 16.17Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.64Profit Margin: -0.72
Significant cash reserves alongside high leverageNotable
Cash (USD): 35,593,000Total Debt (USD): 63,588,000Debt-to-Equity: 3.37
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 5.79Altman Z-Score: 1.05
Financial Health
Altman Z-Score 1.05: distress zoneCritical
Altman Z-Score: 1.05
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Ever Supreme Bio Technology Co., Ltd
Tier 1ProductionApproval-Gated PipelineRuleFlow
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Prothena Corporation plc
Tier 1ProductionApproval-Gated PipelineRuleRisk
Allergy Therapeutics plc
Tier 1ProductionApproval-Gated PipelineRule
Kyverna Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Editas Medicine Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cybin Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Companies that share active interpretations — structural patterns currently present in both stocks.
CrowdStrike Holdings Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Draganfly Inc.
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Rocket Lab Corporation
2 interpretationsUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets